18q21 rearrangement in diffuse large cell lymphoma: Incidence and clinical significance

K. Offit, P. R K Koduru, R. Hollis, D. Filippa, S. C. Jhanwar, B. C. Clarkson, R. S K Chaganti

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Cytogenetic, molecular genetic and clinical information was collected for 102 cases of diffuse large cell lymphoma (DLCL) ascertained in a diagnostic laboratory over a 3-year period. Nineteen cases showed evidence of either a t(14;18) or a rearrangement of one of three genomic probes for breakpoints at 18q21. Clinical and histologic evidence of transformation from follicular lymphoma or chronic lymphocytic leukaemia was available in six cases. Except for age, prognostic clinical variables (LDH, stage, extranodal involvement) were similar between the 18q21 rearranged patients and DLCL patients without 18q21 rearrangement. At a median follow-up in excess of 2 years for both groups, there was no difference in overall survival between the 18q21 rearranged group compared to DLCL patients lacking this genetic abnormality. The median disease-free survival for the 18q21 rearranged group, however, was significantly shorter and survival in partial remission longer. The propensity for extended survival of the 18q21 rearranged DLCL patients with residual or recurrent disease resembled the clinical behaviour of nodular lymphoma patients with t(14;18). These results suggest that cytogenic or molecular genetic identification of a chromosome 18q21 translocation may be of prognostic significance in the analysis of treatment protocols for patients with DLCL.

Original languageEnglish (US)
Pages (from-to)178-183
Number of pages6
JournalBritish Journal of Haematology
Volume72
Issue number2
StatePublished - 1989

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Incidence
Follicular Lymphoma
Survival
Molecular Biology
B-Cell Chronic Lymphocytic Leukemia
Clinical Protocols
Cytogenetics
Disease-Free Survival
Chromosomes

ASJC Scopus subject areas

  • Hematology

Cite this

Offit, K., Koduru, P. R. K., Hollis, R., Filippa, D., Jhanwar, S. C., Clarkson, B. C., & Chaganti, R. S. K. (1989). 18q21 rearrangement in diffuse large cell lymphoma: Incidence and clinical significance. British Journal of Haematology, 72(2), 178-183.

18q21 rearrangement in diffuse large cell lymphoma : Incidence and clinical significance. / Offit, K.; Koduru, P. R K; Hollis, R.; Filippa, D.; Jhanwar, S. C.; Clarkson, B. C.; Chaganti, R. S K.

In: British Journal of Haematology, Vol. 72, No. 2, 1989, p. 178-183.

Research output: Contribution to journalArticle

Offit, K, Koduru, PRK, Hollis, R, Filippa, D, Jhanwar, SC, Clarkson, BC & Chaganti, RSK 1989, '18q21 rearrangement in diffuse large cell lymphoma: Incidence and clinical significance', British Journal of Haematology, vol. 72, no. 2, pp. 178-183.
Offit, K. ; Koduru, P. R K ; Hollis, R. ; Filippa, D. ; Jhanwar, S. C. ; Clarkson, B. C. ; Chaganti, R. S K. / 18q21 rearrangement in diffuse large cell lymphoma : Incidence and clinical significance. In: British Journal of Haematology. 1989 ; Vol. 72, No. 2. pp. 178-183.
@article{53bfec4260f54edb9592a408be60e32d,
title = "18q21 rearrangement in diffuse large cell lymphoma: Incidence and clinical significance",
abstract = "Cytogenetic, molecular genetic and clinical information was collected for 102 cases of diffuse large cell lymphoma (DLCL) ascertained in a diagnostic laboratory over a 3-year period. Nineteen cases showed evidence of either a t(14;18) or a rearrangement of one of three genomic probes for breakpoints at 18q21. Clinical and histologic evidence of transformation from follicular lymphoma or chronic lymphocytic leukaemia was available in six cases. Except for age, prognostic clinical variables (LDH, stage, extranodal involvement) were similar between the 18q21 rearranged patients and DLCL patients without 18q21 rearrangement. At a median follow-up in excess of 2 years for both groups, there was no difference in overall survival between the 18q21 rearranged group compared to DLCL patients lacking this genetic abnormality. The median disease-free survival for the 18q21 rearranged group, however, was significantly shorter and survival in partial remission longer. The propensity for extended survival of the 18q21 rearranged DLCL patients with residual or recurrent disease resembled the clinical behaviour of nodular lymphoma patients with t(14;18). These results suggest that cytogenic or molecular genetic identification of a chromosome 18q21 translocation may be of prognostic significance in the analysis of treatment protocols for patients with DLCL.",
author = "K. Offit and Koduru, {P. R K} and R. Hollis and D. Filippa and Jhanwar, {S. C.} and Clarkson, {B. C.} and Chaganti, {R. S K}",
year = "1989",
language = "English (US)",
volume = "72",
pages = "178--183",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - 18q21 rearrangement in diffuse large cell lymphoma

T2 - Incidence and clinical significance

AU - Offit, K.

AU - Koduru, P. R K

AU - Hollis, R.

AU - Filippa, D.

AU - Jhanwar, S. C.

AU - Clarkson, B. C.

AU - Chaganti, R. S K

PY - 1989

Y1 - 1989

N2 - Cytogenetic, molecular genetic and clinical information was collected for 102 cases of diffuse large cell lymphoma (DLCL) ascertained in a diagnostic laboratory over a 3-year period. Nineteen cases showed evidence of either a t(14;18) or a rearrangement of one of three genomic probes for breakpoints at 18q21. Clinical and histologic evidence of transformation from follicular lymphoma or chronic lymphocytic leukaemia was available in six cases. Except for age, prognostic clinical variables (LDH, stage, extranodal involvement) were similar between the 18q21 rearranged patients and DLCL patients without 18q21 rearrangement. At a median follow-up in excess of 2 years for both groups, there was no difference in overall survival between the 18q21 rearranged group compared to DLCL patients lacking this genetic abnormality. The median disease-free survival for the 18q21 rearranged group, however, was significantly shorter and survival in partial remission longer. The propensity for extended survival of the 18q21 rearranged DLCL patients with residual or recurrent disease resembled the clinical behaviour of nodular lymphoma patients with t(14;18). These results suggest that cytogenic or molecular genetic identification of a chromosome 18q21 translocation may be of prognostic significance in the analysis of treatment protocols for patients with DLCL.

AB - Cytogenetic, molecular genetic and clinical information was collected for 102 cases of diffuse large cell lymphoma (DLCL) ascertained in a diagnostic laboratory over a 3-year period. Nineteen cases showed evidence of either a t(14;18) or a rearrangement of one of three genomic probes for breakpoints at 18q21. Clinical and histologic evidence of transformation from follicular lymphoma or chronic lymphocytic leukaemia was available in six cases. Except for age, prognostic clinical variables (LDH, stage, extranodal involvement) were similar between the 18q21 rearranged patients and DLCL patients without 18q21 rearrangement. At a median follow-up in excess of 2 years for both groups, there was no difference in overall survival between the 18q21 rearranged group compared to DLCL patients lacking this genetic abnormality. The median disease-free survival for the 18q21 rearranged group, however, was significantly shorter and survival in partial remission longer. The propensity for extended survival of the 18q21 rearranged DLCL patients with residual or recurrent disease resembled the clinical behaviour of nodular lymphoma patients with t(14;18). These results suggest that cytogenic or molecular genetic identification of a chromosome 18q21 translocation may be of prognostic significance in the analysis of treatment protocols for patients with DLCL.

UR - http://www.scopus.com/inward/record.url?scp=0024413279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024413279&partnerID=8YFLogxK

M3 - Article

C2 - 2757964

AN - SCOPUS:0024413279

VL - 72

SP - 178

EP - 183

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -